BG
RGLS

BlackRock Group’s Regulus Therapeutics RGLS Stock Holding History

BlackRock Group’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-61
Closed -$24K – 2997
2016
Q3 		$24K Hold
61
– – ﹤0.01% 2969
2016
Q2 		$21K Hold
61
– – ﹤0.01% 2993
2016
Q1 		$51K Buy
61
+37
+154% +$29.4K ﹤0.01% 2919
2015
Q4 		$25K Hold
24
– – ﹤0.01% 2917
2015
Q3 		$19K Buy
+24
New +$24.6K ﹤0.01% 2984
2013
Q4 		– Sell
-141
Closed -$159K – 2764
2013
Q3 		$159K Buy
+141
New +$166K ﹤0.01% 2535

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

BlackRock Group's RGLS Position: Q4 2016 in Review

BlackRock Group sold out of Regulus Therapeutics (RGLS) in Q4 2016, closing a stake of 61 shares — an estimated $24K sold.

BlackRock Group first reported a position in RGLS in Q3 2013 and held it in 6 quarters. The position peaked at $159K in Q3 2013. 68 funds tracked by Wall St. Rank hold RGLS as of Q4 2016.

  • BlackRock Group reported no remaining Regulus Therapeutics position as of Q4 2016 after selling out during the quarter.
  • BlackRock Group sold 61 Regulus Therapeutics shares in Q4 2016, an estimated $24K.
  • BlackRock Group first reported a position in Regulus Therapeutics in Q3 2013 and held it in 6 quarters.
  • BlackRock Group's Regulus Therapeutics position peaked at $159K in Q3 2013.
  • 68 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.